ATEROESCLEROSIS

Pathophysiology of Atherosclerosis
📌 Atherosclerosis is a chronic inflammatory disease affecting medium and large-sized arteries (carotids, coronaries, aorta, mesenterics) characterized by the accumulation of lipids and fibrous thickening.
🧬 The process is rooted in endothelial dysfunction, where the vascular wall loses its anti-inflammatory, anti-thrombotic, and anti-aggregant properties, often triggered by hypertension, dyslipidemia, or smoking.
🧪 The pathogenesis involves a sequence: recruitment of leukocytes to the intima, differentiation into macrophages, and formation of foam cells (macrophages filled with oxidized LDL), which release reactive oxygen species.

Progression and Clinical Manifestations
📈 The disease progresses from fatty streaks (types 1-3) to mature atheromatous plaques (types 4-5) that feature a necrotic core covered by a fibrous cap.
⚠️ Plaque stability is determined by the composition of the fibrous cap; "unstable" plaques have a thin cap and a large lipid core, making them highly susceptible to rupture and thrombosis.
🚨 Clinical consequences such as myocardial infarction or stroke occur when a ruptured or eroded plaque triggers an intra-plaque hemorrhage and subsequent thrombus formation.

Risk Factors and Epidemiological Transition
🧬 Risk factors are categorized as non-modifiable (age, sex, genetics, family history) and modifiable (dyslipidemia, diabetes mellitus, smoking, obesity, chronic inflammation).
🌍 Data from the 2022 Cardiovascular Health Commission confirms that cardiovascular diseases remain the #1 cause of mortality globally, a shift attributed to the epidemiological transition following the control of infectious diseases.
📜 Evidence from studies like the Horus Study (examining 4,000-year-old mummies) and the discovery of the 5,300-year-old "Ötzi" mummy proves that atherosclerosis is not merely a contemporary disease but an ancient condition linked to human biology.

Key Points & Insights
➡️ Focus on the endothelium: The "response to injury" theory highlights that damage to the endothelial monolayer is the cornerstone of atherogenesis.
➡️ Targeting Inflammation: The CANTOS study demonstrated that inhibiting interleukin-1β with monoclonal antibodies significantly reduces cardiovascular events, confirming the clinical importance of the inflammatory pathway.
➡️ Monitor Lipid Profiles: Clinically, maintain a cholesterol level below 200 mg/dL and ensure HDL is above 40 mg/dL to minimize the risk of a highly atherogenic lipid profile.
➡️ Distinguish Plate Types: Remember that stable plaques with heavy calcification may be less dangerous than smaller, lipid-rich plaques with thin fibrous caps, which are prone to acute rupture.

📸 Video summarized with SummaryTube.com on Apr 03, 2026, 17:27 UTC